Bristol Myers Squibb Co. ("Bristol Myers Squibb," "BMS") is an American multinational biopharmaceutical company. It is the legal successor to Bristol-Myers Squibb Company, formed by the 1989 merger of Bristol-Myers Company (founded 1887) and Squibb Corporation (1858). BMS is publicly traded on the NYSE under ticker BMY and is an S&P 500 component. Registered headquarters are in Princeton, New Jersey, with corporate offices in Lawrenceville, New Jersey. Per its FY2025 Form 10-K and earnings release, revenue was approximately $48.2 billion and headcount roughly 32,500; market capitalization was reported in the $117–130 billion range in 2026. It is an independent public company, not a subsidiary.
Products / operations. BMS discovers, develops, manufactures and sells branded biopharmaceuticals and small molecules across oncology, hematology, cardiovascular, immunology and neuroscience. Major marketed products include Eliquis (apixaban), Opdivo (nivolumab), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Orencia (abatacept), Yervoy (ipilimumab) and Reblozyl (luspatercept), with newer launches including Camzyos, Breyanzi and Cobenfy. The 2019 acquisition of Celgene (~$74 billion) brought Revlimid, Pomalyst and Thalomid into the portfolio.
Patent-litigation posture. BMS is an operating company, not a patent assertion entity. The structured data show 3 tracked cases as defendant and 0 as plaintiff — consistent with a large, product-holding pharmaceutical company being targeted, not one asserting patents. Notably, all three tracked matters are payer/pharmacy antitrust actions premised on patent conduct (alleged sham patent litigation and fraudulent procurement concerning Celgene's Revlimid, Pomalyst and Thalomid patents) rather than NPE infringement suits.
Notable cases. The tracked matters are Louisiana Health Service & Indemnity Co. (BCBS LA) et al. v. Celgene Corp. et al. (S.D.N.Y., filed 2023), CenterWell Pharmacy, Inc. v. Celgene Corp. et al. (S.D.N.Y.), and The Cigna Group v. Celgene Corp. et al. (D.N.J., filed 2025). Related litigation in D.N.J. (Cigna, Humana, Molina, Blue Cross plans) alleges reverse-payment and pay-for-delay schemes tied to generic Revlimid entry. Venues are S.D.N.Y. and D.N.J., not plaintiff-friendly patent venues such as the Eastern District of Texas. Reuters reported that in April 2025 Judge Edgardo Ramos dismissed the BCBS Louisiana Pomalyst monopoly claims for failure to plead fraudulent procurement or objectively baseless suits.